Regenxbio (RGNX) Tops Q4 EPS by $1.96

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of $6.67, $1.96 better than the analyst estimate of $4.71. Revenue for the quarter came in at $398.7 million versus the consensus estimate of $271.74 million.

Based on its current operating plan, REGENXBIO expects its balance in cash, cash equivalents and marketable securities of $849.3 million as of December 31, 2021 to fund its operations, including the completion of its internal manufacturing capabilities and clinical advancement of its product candidates, into 2025.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Advance Auto Parts (AAP) Tops Q2 EPS by 22c; lifrs profit guidance
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• Bill.com (BILL) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 Guidance